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Background: Tumor suppressor p53 is mutated in a wide variety of human cancers and plays a critical role in
anoikis, which is essential for preventing tumorigenesis. Recently, we found that a nucleolar protein, Myb-binding
protein 1a (MYBBP1A), was involved in p53 activation. However, the function of MYBBP1A in cancer prevention has
not been elucidated.
Methods: Relationships between MYBBP1A expression levels and breast cancer progression were examined using
patient microarray databases and tissue microarrays. Colony formation, xenograft, and anoikis assays were
conducted using cells in which MYBBP1A was either knocked down or overexpressed. p53 activation and
interactions between p53 and MYBBP1A were assessed by immunoprecipitation and western blot.
Results: MYBBP1A expression was negatively correlated with breast cancer tumorigenesis. In vivo and in vitro
experiments using the breast cancer cell lines MCF-7 and ZR-75-1, which expresses wild type p53, showed that
tumorigenesis, colony formation, and anoikis resistance were significantly enhanced by MYBBP1A knockdown. We
also found that MYBBP1A binds to p53 and enhances p53 target gene transcription under anoikis conditions.
Conclusions: These results suggest that MYBBP1A is required for p53 activation during anoikis; therefore, it is
involved in suppressing colony formation and the tumorigenesis of breast cancer cells. Collectively, our results
suggest that MYBBP1A plays a role in tumor prevention in the context of p53 activation.
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Breast cancer is the most commonly occurring cancer in
women worldwide. It has been estimated that more than
1.6 million new cases of breast cancer occurred in 2010
[1]. Cancer cells develop features that are fundamentally
different from those of normal cells. One hallmark of
cancer cells is their ability to survive and proliferate in
the absence of extracellular matrix (ECM)-derived sig-
nals [2].
The tumor suppressor p53 plays a central role in coor-
dinating the responses to stresses induced by a wide
array of stimuli. Under normal conditions, cellular p53
protein levels are maintained at basal levels. However, in
response to genotoxic stresses, such as exposure to* Correspondence: junny@agbi.tsukuba.ac.jp
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reproduction in any medium, provided the orultraviolet light or γ-irradiation, p53 protein levels in-
crease and trigger either cell cycle arrest or apoptosis
[3]. p53 plays a critical role in cancer prevention, be-
cause p53 can suppress tumorigenesis by inducing cell
cycle arrest and apoptosis through its transcriptional ac-
tivity. p53 is one of the tumor suppressor genes that is
most frequently found to be inactivated in cancer [4].
p53 also plays a critical role in anoikis. Anoikis,
defined as detachment-induced apoptosis [5], reflects
the essential requirement of most normal epithelial cells
for ECM-derived survival signals [6]. When these signals
are denied, for example, upon detachment and contin-
ued culture in suspension or in soft agar, cells will
rapidly undergo cell cycle arrest and apoptosis. The cap-
acity of cancer cells for anchorage-independent growth
under conditions of detachment and suspension in soft
agar correlates well with their tumorigenic potential [2].
p53 is required for anoikis in many cell types [7], includ-
ing epithelial cells [8-12]. Under detached conditions, p53Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/13/65enhances p21, Bax, and PUMA transcription and induces
cell cycle arrest and apoptosis [9,11]. However, the signal-
ing pathways that regulate p53-dependent anoikis are
largely unknown.
Recently, we found that a nucleolar protein, Myb-



















































































Figure 1 MYBBP1A expression decreases as breast cancer carcinogen
breast carcinomas from three independent datasets for human breast canc
[20-22,25]. (B) Decreased MYBBP1A protein expression in carcinoma sample
expression in TMAs and compare it with that of human normal breast tissu
hematoxylin. Representatives of normal breast tissue (1 and 2) and breast c
carcinoma of T2N1aM0, sample 4 is an infiltrating duct carcinoma of T3N2a
6 is an infiltrating duct carcinoma of T2N0M0. The areas within the black sq
bars = 0.5 mm and white scale bars = 100 μm. (C) MYBBP1A protein expres
levels in the cells were determined by immunoblottin.activation. When cells were exposed to cellular stresses,
MYBBP1A translocated from the nucleolus to the nucleo-
plasm. The translocated MYBBP1A promoted p53 acetyl-
ation and accumulation by facilitating the interaction
between p53 and histone acetyltransferase p300; thus,






















































esis progresses. (A) Decreased expression of MYBBP1A mRNA in
ers. Data and statistics were obtained from the Oncomine database
s of breast cancer patients. IHC was used to examine MYBBP1A
es and human breast cancer tissues. Counterstaining used
arcinoma tissue (3 to 6) are shown. Sample 3 is an infiltrating duct
M0, sample 5 is an infiltrating duct carcinoma of T2N0M0, and sample
uares are enlarged and shown in the right-side panels. Black scale
sion levels in MCF-10A, MCF-7, and ZR-75-1 cells. MYBBP1A protein
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http://www.biomedcentral.com/1471-2407/13/65[13]. Previous studies revealed that MYBBP1A was
involved in regulating intracellular energy status, inflam-
mation, and myogenesis [14-16]. In addition, Sanhueza
et al. recently reported that MYBBP1A regulates the
proliferation and migration of head and neck squa-
mous cell carcinoma cells [17]. However, the role
of MYBBP1A in breast cancer prevention and the

















































































































Figure 2 MYBBP1A suppresses colony formation and tumorigenesis i
overexpression in MCF-7 cells. (A) western blot with anti-MYBBP1A antibod
expressed shRNA for MYBBP1A (shMYBBP1A #1 and shMYBBP1A #2), cells t
overexpressed MYBBP1A (OE MYBBP1A), and EGFP (OE Control). (B) MYBBP1
MYBBP1A expression on colony formation. Number of colonies per dish (ar
were inoculated with either shControl, shMYBBP1A #1, OE Control, or OE M
injections of control or cells. Tumor volume is presented as the mean ± s.d
tumor weight in mice injected with shMYBBP1A #1 or OE MYBBP1A cells. P
bars = 10 mm. Tumor weights after 49 days are shown in F, left panel. BarsIn this study, we show that MYBBP1A expression is
associated with breast cancer tumorigenesis through an
extensive analysis of the Oncomine database. In vitro
and in vivo experiments using the breast cancer cell
lines, which expresses wild type p53, revealed that
tumorigenesis, colony formation, and anoikis resistance
were significantly enhanced by MYBBP1A knockdown.
MYBBP1A binds to p53 under detached conditions and
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n vitro and in vivo. (A) and (B) Efficiency of MYBBP1A knockdown and
y was used to detect MYBBP1A protein in MCF-7 cells that stably
hat expressed Luciferase shRNA (shControl), cells that stably
A mRNA in these cells was quantified by RT–qPCR. (C) Effects of
ea = 9.4 cm2) are shown. (D) Tumor growth curves in nude mice that
YBBP1A MCF‐7 cells. Nude mice received bilateral subcutaneous
. (n = 10) for 5 mice in each group. (E) and (F) Increased or decreased
hotographs of mice (E) and tumors (F, right panels) are shown. Scale













































































































































































































































































































































































































































Figure 3 (See legend on next page.)
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Figure 3 MYBBP1A induces anoikis in normal breast and breast cancer cells. (A) MYBBP1A induces anoikis in mammary epithelial cells.
MCF-10A cells were transfected with siRNA for p53 or MYBBP1A; 48 h later, anoikis assay was performed. These cells were cultured under
suspension conditions for 24 h, and viable cell numbers were determined by trypan blue dye exclusion or MTT assay. Protein levels of MYBBP1A
and p53 in the cells were determined by immunoblotting. (B) and (C) MCF-7 and ZR-75-1 cells were transfected with siRNA for 48 h, followed by
anoikis assay, or expressed a plasmid for p53 or MYBBP1A for 24 h followed by anoikis assay. These cells were cultured under suspension
conditions for 24 h, and viable cell numbers were counted or assessed by MTT assay. Protein levels of MYBBP1A and p53 in these cells were
determined by immunoblotting. Bars = mean + s.d. (n = 3).
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These results suggest the physiological significance of
MYBBP1A in p53 activation and cancer prevention.
Methods
Cell culture and transfection
MCF-10A, human mammary epithelial cells, were
maintained in Dulbecco’s modified Eagle’s medium-F12
(DMEM-F12) (Invitrogen, Carlsbad, CA) supplemented
with 0.5 μg/ml hydrocortisone (Sigma-Aldrich, St Louis,
MO), 10 μg/ml insulin (Sigma-Aldrich, St Louis, MO),
and 20 ng/ml recombinant human EGF (Peprotech,
Rocky Hill, NJ). MCF-7 human breast cancer cells were
maintained in DMEM (Sigma-Aldrich, St Louis, MO).
ZR-75-1 human breast cancer cells were maintained in
RPMI 1640 (Nacalai Tesque, Kyoto, Japan). All media
were supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin–streptomycin solution (Nacalai
Tesque, Kyoto, Japan). Transfection was performed
using Lipofectamine LTX (Invitrogen, Carlsbad, CA).
Expression vectors and antibodies
cDNAs encoding full-length p53 and MYBBP1A were
amplified using PCR and subcloned into pcDNA3 plas-
mids (Invitrogen, Carlsbad, CA) and pQCXIP (Clontech,
Mountain View, CA) containing sequences encoding
FLAG sequences. Anti-β-Actin (Sigma-Aldrich, St Louis,
MO) and anti-human-p53 (Santa Cruz, Santa Cruz, CA)
monoclonal antibodies and rabbit anti-p53-K382Ac
(Cell Signaling Technology, Danvers, MA) polyclonal
antibody were used according to the manufacturers’
instructions. Rabbit anti-human MYBBP1A antibody
was raised against a synthetic peptide corresponding to
amino acids 1265–1328 of human MYBBP1A.
Oncomine analysis
The Oncomine database and gene microarray analysis
tool, a repository for published complementary DNA
microarray data [18,19], were explored (July 2012) for
MYBBP1A mRNA expression in non-neoplastic and
breast cancer tissues. Statistical analysis of the diffe-
rences in MYBBP1A expression between these tissues
used Oncomine algorithms, which provided multiple
comparisons among different studies [20-22]. Data
sets obtained from TCGA Breast, Finak Breast, andRichardson Breast 2 included various stage, and all
cancer samples were invasive.
Immunohistochemistry (IHC)
Human breast cancer tissue microarrays were purchased
from SuperBioChips Laboratories (Seoul, Korea) included
various stages, and all cancer samples were invasive.
Formalin-fixed tissues were dewaxed in xylene and rehy-
drated in alcohol. For antigen retrieval, the sections were
subsequently heated in EDTA buffer (1 mM, pH 8.0) in a
microwave oven for 5 min. Endogenous peroxidase acti-
vity was suppressed using a solution of 3% hydrogen
peroxide in methanol for 6 min. The samples were stained
with avidin–biotin–peroxidase complexes using a Histo-
fine SAB-PO Immunohistochemical Staining Kit (Nichirei,
Tokyo, Japan) according to the manufacturer’s instruc-
tions. Rabbit anti-MYBBP1A antibody was used at a dilu-
tion of 1:50.
RNA interference
Methods for stable RNA interference followed those
described by Kajiro et al. [23]. To generate a shRNA retro-
viral supernatant, GP2-293 cells (Clontech, Mountain View,
CA) were co-transfected with a p10A1 vector encoding an
envelope protein and pRETRO-SUPER (Oligo Engine,
Seattle, WA) vector containing either the MYBBP1A or luci-
ferase (control) target sequence. MCF-7 cells were incubated
with the retroviral supernatant in the presence of 8 μg/ml
polybrene. Infected cells were selected using 1 μg/ml of
puromycin. The target sequences were 50- TTCAGGGCA
TATTTCATCTCGGACC-30 for MYBB1A #1, 50-TTCA
GGGCATATTTCATCTCGGACC-30 for MYBBP1A #2,
and 50-GAAGCTGCGCGGTGGTGTTGT-30 for luciferase.
For siRNA transfection, cells at 30%–50% confluency were
transfected using Lipofectamine RNAi MAX (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol. All
siRNAs were purchased from Invitrogen. The siRNA
duplexes were MYBBP1A, 50-UCUUUCAGUCAGGU
CGGCUGGUGAA-30 and p53, 50-CCAGUGGUAAUCUA
CUGGGACGGAA-30. Stealth RNAi negative control was
used as a negative control.
Tumor xenograft models
All animal experiments were performed in accordance
with institutional guidelines. The tumor xenograft
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was subcutaneously injected with 100 μl of cell suspen-
sion (5 × 106) in both flanks. At the time points indicated
in the figures, the tumors were excised, weighed, and


































































































































































































































































Figure 4 MYBBP1A induces anoikis in a p53-dependent manner. (A) a
MCF-7 and ZR-75-1 cells were transfected with a plasmid for MYBBP1A exp
suspension conditions for 24 h, and viable cell numbers were counted usin
MYBBP1A and p53 in the cells were determined by immunoblotting. Bars =Soft agar colony-formation assay
For soft agar assays, 22,000 cells were mixed with 1 ml
of 0.35% top agar and plated onto a 35-mm six-well
plate containing bottom plugs (0.6% agar, 10% FBS, 1×






































































































































































nd (B) p53 is required for MYBBP1A-induced anoikis. As indicated,
ression with or without siRNA for p53. These cells were cultured under
g trypan blue dye exclusion or assessed by MTT assay. Protein levels of
mean + s.d. (n = 3).
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vent dehydration. This covering medium was changed
every 2 or 3 days during culture. After allowing growth
for 2 weeks at 37°C, colonies with a diameter of
>100 μm were counted.
Anoikis assay
MCF-10A cells were plated at a density of 3 × 105
cells per well in six-well plates in an ultra-low at-
tachment culture dish (Corning, Tewksbury, MA)
and maintained in DMEM-F12 (Invitrogen, Carlsbad,
CA) supplemented with 10% FBS, 0.5 μg/ml hydro-
cortisone (Sigma-Aldrich, St Louis, MO), 10 μg/ml
insulin (Sigma-Aldrich, St Louis, MO), and 20 ng/ml
recombinant human EGF (Peprotech, Rocky Hill,
NJ). MCF-7 cells were plated at a density of 3 × 105
cells per well in DMEM with 5% FBS. ZR-75-1 cells
were plated at a density of 3 × 105 cells per well in
RPMI 1640 with 10% FBS. All media were supple-
mented with 1% penicillin–streptomycin solution
(Nacalai Tesque, Kyoto, Japan). Before analysis, the
samples were treated with trypsin to disperse the
cells. Cell viability after detachment was determined
by trypan blue dye exclusion. Viable cells were
determined by MTT assay using an MTT cell count-
ing kit (Nacalai Tesque, Kyoto, Japan). Apoptotic cell
proportion was determined by fluorescence-activated
cell sorting (FACS) analysis using PI and fluoresceinA
siControl siMYBBsip53

















Figure 5 MYBBP1A induces apoptosis during detached conditions in
siRNA or a plasmid for p53 or MYBBP1A expression for 48 h, followed by an
24 h, and apoptotic cells were determined by Annexin V–FITC/PI staining f
induced anoikis. As indicated, MCF-7 cells were transfected with a plasmid
cultured under suspension conditions for 24 h, after which apoptotic cells
cytometry analyses.isothiocyanate (FITC)-conjugated Annexin V (MBL,
Tokyo, Japan) staining.
Real-time RT-PCR
Real-time RT-PCR was performed as described previ-
ously [24]. Cells were homogenized in 1 ml Isogen
(Nippon Gene, Tokyo, Japan), and the total RNA
was extracted according to the instruction manual.
cDNA was synthesized from total RNA using Rever-
Tra Ace reverse transcriptase (Toyobo, Osaka, Japan)
and oligo dT primers. Real-time PCR was used to
amplify fragments representing the indicated mRNA
expressions. The primer sequences used were as
follows:
GAPDH fw primer: 50-
GTATGACTCCACTCACGGCAAA -30
GAPDH rv primer: 50-
GGTCTCGCTCCTGGAAGATG-30
p21 fw primer: 50-GGAGACTCTCAGGGTCGAAA-30
p21 rv primer: 50-TTAGGGCTTCCTCTTGGAGA-30
Bax fw primer: 50-AGCAAACTGGTGCTCAAGG -30
Bax rw primer: 50-CTTGGATCCAGCC
CAACAG -30
PUMA fw primer: 50-
GGGCCCAGACTGTGAATCCT-30























a p53-dependent manner. (A) MCF-7 cells were transfected with
oikis assay. These cells were cultured under suspension conditions for
ollowed by flow cytometry analyses. (B) p53 is required for MYBBP1A-
for MYBBP1A expression with or without siRNA for p53. They were then
were determined by Annexin V–FITC/PI staining and flow
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Cells were lysed in TNE buffer [10 mM Tris–HCl
(pH 7.8), 1% Nonidet P-40 (NP-40), 0.15 M NaCl,
1 mM ethylenediaminetetraacetic acid (EDTA), 1 M
phenylmethylsulfonyl fluoride (PMSF), 1 g/ml aprotinin].
The extracted proteins were immunoprecipitated with
antibody-coated protein G Sepharose beads (GE Health-
care Japan, Tokyo, Japan). Bound proteins were sepa-
rated by SDS–PAGE, transferred to polyvinylidene
difluoride membranes (Millipore, Temecula, CA), and
detected with appropriate primary antibodies and horse-
radish peroxidase-conjugated secondary antibodies.
Specific proteins were visualized using an enhanced
chemiluminescence (ECL) western blot detection system
























































































































































































Figure 6 MYBBP1A enhances p53 target genes’ expression during an
48 h prior to anoikis assay and cultured under attached or detached condi
were prepared and expressions of the indicated genes were analyzed by RChromatin immunoprecipitation (ChIP) and real-time PCR
detection
ChIP assay was performed according to the published
procedures [24]. The primers for real-time PCR were as
follows: forward, TAATCCCAGCGCTTTGGAAG; re-
verse, TTGCTAGATCCAGGTCTCTGCA for the up-
stream region of the Bax gene.
Immunofluorescence
Cells were fixed in 3.7% formaldehyde in PBS for
10 min. After rinsing twice with PBS, the cells were per-
meabilized in 0.1% Triton X-100 in PBS and later
blocked with TBS-T buffer containing 0.5% bovine
serum albumin and 10% goat serum for 1 h at room













































































































































oikis. (A) and (B) MCF-7 and ZR-75-1 cells were treated with siRNAs for
tions for 2 h (Bax mRNA) or 4 h (PUMA and p21 mRNA). Total RNAs
T–qPCR. Bars = mean + s.d. (n = 3).
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ned with Alexa Fluor-conjugated secondary antibodies
(Invitrogen, Carlsbad, CA) for 1 h, and mounted with
Vectashield (Vector Laboratories, Burlingame, CA). Im-
munofluorescent images were obtained by Biozero im-
munofluorescence microscopy (Keyence, Osaka, Japan).
Results
MYBBP1A expression decreases as breast cancer
carcinogenesis progresses
We previously reported that MYBBBP1A was involved
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Figure 7 MYBBP1A enhances p53 activation during anoikis. (A) Acetyl
requires MYBBP1A. MCF-7 cells were treated with siControl or siMYBBP1A f
2 h. Cell lysates were analyzed by immunoblot using the indicated antibod
conditions requires MYBBP1A. MCF-7 cells were treated as shown in (A), an
antibodies. The p53-binding region of the Bax promoter was amplified and
to the nucleoplasm under detached conditions. MCF-7 cells were cultured
localizations of MYBBP1A and p53 were visualized by immunofluorescence
MYBBP1A associates with p53 under detached conditions. MCF-7 cells were
immunoprecipitated with normal rabbit IgG or anti-MYBBP1A antibodies an
p53. Bars = mean + s.d. (n = 3).MYBBP1A would have a cancer prevention function via
p53. To examine the relationship between MYBBP1A
expression and breast cancer progression, we examined
the MYBBP1A expression profiles in breast carcinomas
compared to those of normal tissue using the Oncomine
database, which provides publicly available datasets of
gene expression in cancer. Of the 12 datasets, 11 con-
tained gene chip profiles classified as normal or breast
carcinoma tissues, which indicated that MYBBP1A
mRNA levels were significantly lower in breast carci-
nomas than in normal tissues. Three representative

































1 2 3 4 5 6 7 8
ation at lysine 382 residues of p53 induced under detached conditions
or 48 h followed by culture under attached or detached conditions for
ies. (B) p53 recruitment to the Bax promoter under detached
d ChIP assay was performed using normal mouse IgG and anti-p53
analyzed by RT–qPCR. (C) MYBBP1A translocates from the nucleolus
under attached or detached conditions for 2 h, after which the
using anti-MYBBP1A and anti-p53 antibodies. (D) Endogenous
cultured under detached conditions for 2 h. The cell lysates were
d analyzed by immunoblot using antibodies against MYBBP1A and
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expression levels in normal vs. breast carcinoma;
P = 2.95E-25, 2.10E-6, and 7.17E-4). Next, we used IHC
to assess MYBBP1A expression in non-neoplastic and
breast cancer tissues using a human breast cancer tissue
microarray. As shown in Figure 1B, MYBBP1A expres-
sion was significantly decreased in the breast cancer
tumors. To confirm these results, we compared
MYBBP1A protein levels in MCF-10A, MCF-7, and
ZR-75-1 cells. The MYBBP1A protein levels were much
lower in MCF-7 and ZR-75-1 cells, the cancer cell
lines derived from human breast cancer cells, than in
MCF-10A cells, a normal breast tissue cell line
(Figure 1C). These results suggested that MYBBP1A had
an inhibitory effect on carcinogenesis in these cancer
patients.
MYBBP1A suppresses colony formation and
tumorigenesis in vitro and in vivo
To investigate a possible relationship between MYBBP1A
and breast cancer cell growth, we generated MCF-7
cells that had stably knocked down or overexpressed
MYBBP1A (Figure 2A and 2B). MCF-7 is a breast cancer
cell line that expresses wild type p53. As shown in
Figure 2C, the colony numbers in soft agar were marked-
ly increased when using MYBBP1A knockdown cells
(shMYBBP1A #1 and shMYBBP1A sh#2). Conversely,
MYBBP1A overexpression decreased the number of these
colonies (Figure 2C: OE MYBBP1A).
Next, we performed xenograft experiments to test
the effect of MYBBP1A expression on tumorigenicity
in vivo. MYBBP1A knockdown cells formed tumors that
were significantly larger than those of control cells. In
contrast, MYBBP1A overexpressing cells formed smaller







Figure 8 Proposed model for the role of MYBBP1A in p53 dependentresults indicated that MYBBP1A could suppress breast
cancer tumor growth.
MYBBP1A induces anoikis in a p53-dependent manner
To examine how MYBBP1A could suppress tumor for-
mation we focused on anoikis, because p53 plays a crit-
ical role in anoikis [7-12]. Thus, we examined whether
MYBBP1A was involved in anoikis in the context of the
p53 pathway. MCF-10A mammary epithelial cells were
transfected with sip53 or siMYBBP1A and cultured in
non-adherent plates for 24 h. The number of viable cells
under detached conditions increased with p53 or
MYBBP1A knockdown (Figure 3A). MCF-7 and ZR-75-1
breast cancer cells were also cultured under detached
conditions. The number of viable cells increased with
p53 knockdown, while they decreased when p53
was overexpressed. Similarly, MYBBP1A knockdown
increased and MYBBP1A overexpression decreased the
numbers of viable cells under detached conditions
(Figure 3B and 3C). These results indicated that
MYBBP1A was involved in anoikis in breast tissues.
To confirm that MYBBP1A was involved in anoikis in
context of p53 activation, we tested the combination of
p53 knockdown and MYBBP1A overexpression in anoi-
kis assay using MCF-7 cells (Figure 4A). Based on
previous results (Figure 3B), MYBBP1A overexpression
decreased the number of viable cells (compare lanes 1
and 2 in Figure 4A). However, MYBBP1A overexpression
in p53 knocked-down cells did not show any significant
effects (compare lanes 3 and 4 in Figure 4A). Similar
results were obtained in ZR-75-1 cells (Figure 4B).
To further examine the role of MYBBP1A in anoikis,
we examined cellular apoptosis as determined by
Annexin V–FITC/PI staining, followed by flow cyto-





anoikis. See the text.
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MYBBP1A knockdown and increased when these genes
were overexpressed (Figure 5A). Moreover, MYBBP1A
overexpression in p53 knocked-down cells did not result
in any significant effects (Figure 5B). These results indi-
cate that MYBBP1A regulates p53-dependent anoikis.
MYBBP1A enhances p53 target genes expression during
anoikis
Next, the effects of MYBBP1A knockdown on the induc-
tion of p53-target genes were examined. The mRNA levels
of Bax, PUMA, and p21 were increased under detached
conditions, whereas the increases in these mRNA levels
were suppressed when MYBBP1A was knocked down
using siRNA in MCF-7 cells (Figure 6A). Similar results
were obtained with ZR-75-1 cells (Figure 6B). These
results suggest that MYBBP1A regulates p53-dependent
anoikis by enhancing p53 activation.
MYBBP1A enhances p53 activation during anoikis
The acetylation levels of p53 are increased in re-
sponse to stress and correlate well with p53 activation
and stabilization [26-28]. Accumulating evidence sup-
ports the conclusion that acetylation stabilizes p53
and is indispensable for p53 activation [29,30]. There-
fore, to study the molecular mechanism by which
MYBBP1A induced anoikis in a p53-dependent man-
ner, we examined whether MYBBP1A was involved
in the accumulation of p53 protein and the acetyl-
ation of p53 K382 under detached conditions. Im-
munoblotting revealed that detached conditions
induced the accumulation and acetylation of p53
(Figure 7A lane 3). However, p53 accumulation and
acetylation were not observed when MYBBP1A was
knocked down using siRNA (Figure 7A lane 4). This
suggested that MYBBP1A was required for p53 acti-
vation in anoikis.
Consistent with these results, p53 recruitment to the
Bax promoter was significantly enhanced under detached
conditions, while p53 recruitment was abrogated by
MYBBP1A knockdown (Figure 7B).
A previous report showed that MYBBP1A activates
p53 by facilitating its direct interaction with p53 in re-
sponse to stress when MYBBP1A translocated from the
nucleolus to the nucleoplasm [13]. Therefore, we exam-
ined the localization of MYBBP1A and the interaction
between MYBBP1A and p53 under detached conditions.
Immunostaining revealed that MYBBP1A translocated
from the nucleolus to the nucleoplasm under detached
conditions (Figure 7C). Moreover, co-immunoprecipitation
showed that endogenous MYBBP1A was bound to p53 in
MCF-7 cells under detached conditions (Figure 7D). These
results indicated that, under detached conditions,
MYBBP1A translocates from the nucleolus to thenucleoplasm, and then binds to p53. Thus, MPBBP1A
enhances p53 target gene transcription.
Discussion
In this study, we revealed the physiological significance
of MYBBP1A in p53 activation for prevention of cancer.
MYBBP1A was originally identified as a protein that
interacted with the negative regulatory domain of c-Myb
[31]. However, in studies done by a number of different
groups, MYBBP1A was found to interact with and regu-
late several transcription factors. MYBBP1A binds to
Prep1 or PGC-1α and inhibits their activity. Prep1
is involved in development and organogenesis, and
PGC-1α is a key regulator of metabolic processes
such as mitochondrial biogenesis, respiration, and
gluco neogenesis in the liver [32,33]. Correspondingly,
MYBBBP1A also interacts with NF–κB and CRY1 and
regulates their transcriptional activity [15,34].
We previously reported that MYBBP1A interacts with
p53 and activates its transcriptional capacity. MYBBP1A
localizes predominantly in the nucleolus; however, it
translocates from the nucleolus to the nucleoplasm in
response to cellular stress and activates p53 [13,14,35].
Similar to other kinds of stress, detached conditions in-
duce p53 acetylation and target gene transcription in an
MYBBP1A-dependent manner (Figures 6 and 7A).
MYBBP1A plays an important role in p53 activation in
response to detached condition to induce anoikis.
The regulation of MYBBP1A localization under
detached conditions is still to be elucidated. When cells
are exposed to UV light, MYBBP1A translocation is
accompanied by nucleolar segregation [13]. Because the
nucleolus appears to be intact after 2 h under detached
conditions, there may be another signal that releases
MYBBP1A from the nucleolus.
Numerous reports have shown that other nucleolar
proteins can activate p53 similar to that by MYBBP1A.
RPL11 directly bind to HDM2 and inhibit HDM2-
mediated p53 ubiquitination [36-41]. Similarly, the nu-
cleolar proteins NPM, NCL, NS, and ARF can also dir-
ectly bind to HDM2 and inhibit p53 ubiquitination
[42-46]. Unlike with these nucleolar factors, MYBBP1A
promotes p53 activation by directly binding to p53
without affecting HDM2 function. With regard to the
pronounced effect of MYBBP1A knockdown on p53 ac-
cumulation and acetylation under detached conditions
(Figure 7A), MYBBP1A may have a unique and essential
function in response to detached conditions.
In addition, Sanhueza et al. recently reported that
MYBBP1A regulates the proliferation and migration of
head and neck squamous cell carcinoma cells [17]. How-
ever, the detailed mechanisms underlying these activities
are unknown. In this study, we revealed a function for
the nucleolar protein MYBBP1A in breast cancer.
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http://www.biomedcentral.com/1471-2407/13/65Therefore, our results provide a novel insight into the
function of the nucleolar protein MYBBP1A in the biol-
ogy of cancer cells.Conclusion
To determine the role of MYBBP1A in cancer, we con-
ducted an extensive analysis of the Oncomine database
and IHC studies, and showed that MYBBP1A expression
was associated with breast cancer tumorigenesis. In vivo
and in vitro experiments using the breast cancer cell
lines revealed that tumorigenesis, colony formation,
and anoikis resistance were significantly enhanced by
MYBBP1A knockdown. Co-immunoprecipitation experi-
ments revealed that MYBBP1A binds to p53 under
detached conditions and enhances p53 target gene tran-
scription (Figure 8). These results revealed the physio-
logical significance of MYBBP1A in p53 activation. Our
results may lead to a novel strategy for breast cancer
therapy.
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